Psychiatry Research: Neuroimaging
Volume 163, Issue 2 , Pages 171-182 , 15 July 2008

Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA

  • Vanessa L. Cropley

      Affiliations

    • Molecular Imaging Branch, National Institute of Mental Health, Bethesda, MD, USA
    • Brain Sciences Institute, Swinburne University of Technology, Hawthorn, Victoria, Australia
    • Corresponding Author InformationCorresponding authors. National Institute of Mental Health, National Institutes of Health, Bldg. 31, Rm. B2-B37, 1 Center Drive, MSC 0135, Bethesda, MD 20892-0135, USA. Tel.: +301 594 1368; fax: +301 480 3610.
    • ,
  • Masahiro Fujita

      Affiliations

    • Molecular Imaging Branch, National Institute of Mental Health, Bethesda, MD, USA
    • ,
  • William Bara-Jimenez

      Affiliations

    • Human Motor Control Section, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA
    • ,
  • Amira K. Brown

      Affiliations

    • Molecular Imaging Branch, National Institute of Mental Health, Bethesda, MD, USA
    • ,
  • Xiang-Yang Zhang

      Affiliations

    • Molecular Imaging Branch, National Institute of Mental Health, Bethesda, MD, USA
    • ,
  • Janet Sangare

      Affiliations

    • Molecular Imaging Branch, National Institute of Mental Health, Bethesda, MD, USA
    • ,
  • Peter Herscovitch

      Affiliations

    • PET Department, Clinical Center, National Institutes of Health, Bethesda, MD, USA
    • ,
  • Victor W. Pike

      Affiliations

    • Molecular Imaging Branch, National Institute of Mental Health, Bethesda, MD, USA
    • ,
  • Mark Hallett

      Affiliations

    • Human Motor Control Section, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA
    • ,
  • Pradeep J. Nathan

      Affiliations

    • School of Psychology, Psychiatry and Psychological Medicine, Monash University, Clayton, Victoria, Australia
    • ,
  • Robert B. Innis

      Affiliations

    • Molecular Imaging Branch, National Institute of Mental Health, Bethesda, MD, USA
    • Corresponding Author InformationCorresponding authors. National Institute of Mental Health, National Institutes of Health, Bldg. 31, Rm. B2-B37, 1 Center Drive, MSC 0135, Bethesda, MD 20892-0135, USA. Tel.: +301 594 1368; fax: +301 480 3610.

Received 15 August 2007 ,Revised 12 November 2007 ,Accepted 14 November 2007.

References 

  1. Abi-Dargham A, Martinez D, Mawlawi O, Simpson N, Hwang DR, Slifstein M, et al. Measurement of striatal and extrastriatal dopamine D1 receptor binding potential with [11C]NNC 112 in humans: validation and reproducibility. Journal of Cerebral Blood Flow and Metabolism. 2000;20:225–243
  2. Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. Journal of Neuroscience. 2002;22:3708–3719
  3. Adam MJ, Jivan S. Synthesis and purification of l-6-[18 F]fluorodopa. Applied Radiation and Isotopes. 1998;39:1203–1206
  4. Alexander GE, Crutcher MD, DeLong MR. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, “prefrontal” and “limbic” functions. Progress in Brain Research. 1990;85:119–146
  5. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annual Review of Neuroscience. 1986;9:357–381
  6. Arnsten AF. Catecholamine regulation of the prefrontal cortex. Journal of Psychopharmacology. 1997;11:151–162
  7. Arnsten AF. Catecholamine modulation of prefrontal cortical cognitive function. Trends in Cognitive Sciences. 1998;2:436–447
  8. Beck AT, Steer RA, Brown GK. BDI-FastScreen for Medical Patients. USA: The Psychological Corporation; 2000;
  9. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society. Series B. 1995;57:289–300
  10. Bilder RM, Volavka J, Lachman HM, Grace AA. The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology. 2004;29:1943–1961
  11. Bowen FP, Kamienny RS, Burns MM, Yahr M. Parkinsonism: effects of levodopa treatment on concept formation. Neurology. 1975;25:701–704
  12. Brown RG, Marsden CD. An investigation of the phenomenon of “set” in Parkinson's disease. Movement Disorders. 1988;3:152–161
  13. Bruck A, Aalto S, Nurmi E, Bergman J, Rinne JO. Cortical 6-[18F]fluoro-l-dopa uptake and frontal cognitive functions in early Parkinson's disease. Neurobiology of Aging. 2005;26:891–898
  14. Bruck A, Portin R, Lindell A, Laihinen A, Bergman J, Haaparanta M, et al. Positron emission tomography shows that impaired frontal lobe functioning in Parkinson's disease is related to dopaminergic hypofunction in the caudate nucleus. Neuroscience Letters. 2001;311:81–84
  15. Canavan AG, Passingham RE, Marsden CD, Quinn N, Wyke M, Polkey CE. The performance on learning tasks of patients in the early stages of Parkinson's disease. Neuropsychologia. 1989;27:141–156
  16. Chou YH, Karlsson P, Halldin C, Olsson H, Farde L. A PET study of D1-like dopamine receptor ligand binding during altered endogenous dopamine levels in the primate brain. Psychopharmacology. 1999;146:220–227
  17. Cools R. Dopaminergic modulation of cognitive function-implications for l-DOPA treatment in Parkinson's disease. Neuroscience and Biobehavioral Reviews. 2006;30:1–23
  18. Cools R, Barker RA, Sahakian BJ, Robbins TW. l-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. Neuropsychologia. 2003;41:1431–1441
  19. Cools R, Stefanova E, Barker RA, Robbins TW, Owen AM. Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. Brain. 2002;125:584–594
  20. Cropley VL, Fujita M, Innis RB, Nathan PJ. Molecular imaging of the dopaminergic system and its association with human cognitive function. Biological Psychiatry. 2006;59:898–907
  21. De Keyser J, Claeys A, De Backer JP, Ebinger G, Roels F, Vauquelin G. Autoradiographic localization of D1 and D2 dopamine receptors in the human brain. Neuroscience Letters. 1988;91:142–147
  22. Dubois B, Pillon B. Cognitive deficits in Parkinson's disease. Journal of Neurology. 1997;244:2–8
  23. Duchesne N, Soucy JP, Masson H, Chouinard S, Bedard MA. Cognitive deficits and striatal dopaminergic denervation in Parkinson's disease: a single photon emission computed tomography study using 123iodine-beta-CIT in patients on and off levodopa. Clinical Neuropharmacology. 2002;25:216–224
  24. Durstewitz D, Seamans JK, Sejnowski TJ. Dopamine-mediated stabilization of delay-period activity in a network model of prefrontal cortex. Journal of Neurophysiology. 2000;83:1733–1750
  25. Ekelund J, Slifstein M, Narendran R, Guillin O, Belani H, Guo NN, et al. In vivo DA D1 receptor selectivity of NNC 112 and SCH 23390. Molecular Imaging and Biology. 2007;9:117–125
  26. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research. 1975;12:189–198
  27. Giovacchini G, Lerner A, Toczek MT, Fraser C, Ma K, DeMar JC, et al. Brain incorporation of 11C-arachidonic acid, blood volume, and blood flow in healthy aging: a study with partial-volume correction. Journal of Nuclear Medicine. 2004;45:1471–1479
  28. Hall H, Sedvall G, Magnusson O, Kopp J, Halldin C, Farde L. Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology. 1994;11:245–256
  29. Halldin C, Foged C, Chou YH, Karlsson P, Swahn CG, Sandell J, et al. Carbon-11-NNC 112: a radioligand for PET examination of striatal and neocortical D1-dopamine receptors. Journal of Nuclear Medicine. 1998;39:2061–2068
  30. Hayes AE, Davidson MC, Keele SW, Rafal RD. Toward a functional analysis of the basal ganglia. Journal of Cognitive Neuroscience. 1998;10:178–198
  31. Heaton RK, Goldin JN. Wisconsin Card Sorting Test: Computer Version 4 Research Edition. Lutz, FL: Psychological Assessment Resources; 2003;
  32. Heiss WD, Hilker R. The sensitivity of 18-fluorodopa positron emission tomography and magnetic resonance imaging in Parkinson's disease. European Journal of Neurology. 2004;11:5–12
  33. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427–442
  34. Holthoff-Detto VA, Kessler J, Herholz K, Bonner H, Pietrzyk U, Wurker M, et al. Functional effects of striatal dysfunction in Parkinson disease. Archives of Neurology. 1997;54:145–150
  35. Ichise M, Liow JS, Lu JQ, Takano A, Model K, Toyama H, et al. Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. Journal of Cerebral Blood Flow and Metabolism. 2003;23:1096–1112
  36. Ikemoto K, Kitahama K, Nishimura A, Jouvet A, Nishi K, Arai R, et al. Tyrosine hydroxylase and aromatic l-amino acid decarboxylase do not coexist in neurons in the human anterior cingulate cortex. Neuroscience Letters. 1999;269:37–40
  37. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. Journal of Cerebral Blood Flow and Metabolism. 2007;27:1533–1539
  38. Ito K, Nagano-Saito A, Kato T, Arahata Y, Nakamura A, Kawasumi Y, et al. Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-l-dopa PET study. Brain. 2002;125:1358–1365
  39. Jenkinson M, Smith S. A global optimisation method for robust affine registration of brain images. Medical Image Analysis. 2001;5:143–156
  40. Jurica PJ, Leitten CL, Mattis S. Dementia Rating Scale-2: Professional manual. Odessa, FL: Psychological Assessment Resources; 2001;
  41. Kaasinen V, Nurmi E, Bruck A, Eskola O, Bergman J, Solin O, et al. Increased frontal [18F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex. Brain. 2001;124:1125–1130
  42. Karlsson P, Farde L, Halldin C, Sedvall G. D1-dopamine receptors in schizophrenia examined by PET. Schizophrenia Research. 1997;24:178–179
  43. Lange KW, Paul GM, Robbins TW, Marsden CD. l-dopa and frontal cognitive function in Parkinson's disease. Advances in Neurology. 1993;60:475–478
  44. Lange KW, Robbins TW, Marsden CD, James M, Owen AM, Paul GM. l-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology. 1992;107:394–404
  45. Lawrence AD, Weeks RA, Brooks DJ, Andrews TC, Watkins LH, Harding AE, et al. The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease. Brain. 1998;121(Pt 7):1343–1355
  46. Mackay AV, Davies P, Dewar AJ, Yates CM. Regional distribution of enzymes associated with neurotransmission by monoamines, acetylcholine and GABA in the human brain. Journal of Neurochemistry. 1978;30:827–839
  47. Marie RM, Barre L, Dupuy B, Viader F, Defer G, Baron JC. Relationships between striatal dopamine denervation and frontal executive tests in Parkinson's disease. Neuroscience Letters. 1999;260:77–80
  48. Monchi O, Petrides M, Strafella AP, Worsley KJ, Doyon J. Functional role of the basal ganglia in the planning and execution of actions. Annals of Neurology. 2006;59:257–264
  49. Müller-Gartner HW, Links JM, Prince JL, Bryan RN, McVeigh E, Leal JP, et al. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. Journal of Cerebral Blood Flow and Metabolism. 1992;12:571–583
  50. Müller U, Wachter T, Barthel H, Reuter M, von Cramon DY. Striatal [123I]beta-CIT SPECT and prefrontal cognitive functions in Parkinson's disease. Journal of Neural Transmission. 2000;107:303–319
  51. Nagano AS, Ito K, Kato T, Arahata Y, Kachi T, Hatano K, et al. Extrastriatal mean regional uptake of fluorine-18-FDOPA in the normal aged brain—an approach using MRI-aided spatial normalization. Neuroimage. 2000;11:760–766
  52. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature. 1997;385:634–636
  53. Ouchi Y, Kanno T, Okada H, Yoshikawa E, Futatsubashi M, Nobezawa S, et al. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study. Annals of Neurology. 1999;46:723–731
  54. Owen AM. Cognitive dysfunction in Parkinson's disease: the role of frontostriatal circuitry. Neuroscientist. 2004;10:525–537
  55. Owen AM, James M, Leigh PN, Summers BA, Marsden CD, Quinn NP, et al. Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain. 1992;115(Pt 6):1727–1751
  56. Paolo AM, Troster AI, Axelrod BN, Koller WC. Construct validity of the WCST in normal elderly and persons with Parkinson's disease. Archives of Clinical Neuropsychology. 1995;10:463–473
  57. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. Journal of Cerebral Blood Flow and Metabolism. 1985;5:584–590
  58. Rakshi JS, Uema T, Ito K, Bailey DL, Morrish PK, Ashburner J, et al. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [18F]dopa-PET study. Brain. 1999;122(Pt 9):1637–1650
  59. Rinne JO, Portin R, Ruottinen H, Nurmi E, Bergman J, Haaparanta M, et al. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study. Archives of Neurology. 2000;57:470–475
  60. Roberts AC, De Salvia MA, Wilkinson LS, Collins P, Muir JL, Everitt BJ, et al. 6-Hydroxydopamine lesions of the prefrontal cortex in monkeys enhance performance on an analog of the Wisconsin Card Sort Test: possible interactions with subcortical dopamine. Journal of Neuroscience. 1994;14:2531–2544
  61. Shallice T. Specific impairments of planning. Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences. 1982;298:199–209
  62. Shinotoh H, Inoue O, Hirayama K, Aotsuka A, Asahina M, Suhara T, et al. Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study. Journal of Neurology, Neurosurgery and Psychiatry. 1993;56:467–472
  63. Slifstein M, Kegeles LS, Gonzales R, Frankle WG, Xu X, Laruelle M, et al. [11C]NNC 112 selectivity for dopamine D1 and serotonin 5-HT2A receptors: a PET study in healthy human subjects. Journal of Cerebral Blood Flow and Metabolism. 2007;27:1733–1741
  64. Suhara T, Fukuda H, Inoue O, Itoh T, Suzuki K, Yamasaki T, et al. Age-related changes in human D1 dopamine receptors measured by positron emission tomography. Psychopharmacology. 1991;103:41–45
  65. Taylor AE, Saint-Cyr JA, Lang AE. Frontal lobe dysfunction in Parkinson's disease. The cortical focus of neostriatal outflow. Brain. 1986;109(Pt 5):845–883
  66. Turjanski N, Lees AJ, Brooks DJ. In vivo studies on striatal dopamine D1 and D2 site binding in l-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology. 1997;49:717–723
  67. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273–289
  68. Wang Y, Chan GL, Holden JE, Dobko T, Mak E, Schulzer M, et al. Age-dependent decline of dopamine D1 receptors in human brain: a PET study. Synapse. 1998;30:56–61

PII: S0925-4927(07)00230-2

doi: 10.1016/j.pscychresns.2007.11.003

Psychiatry Research: Neuroimaging
Volume 163, Issue 2 , Pages 171-182 , 15 July 2008

Article Tools

* Image Usage & Resolution